X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ALEMBIC LTD - Comparison Results

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA ALEMBIC LTD PLETHICO PHARMA/
ALEMBIC LTD
 
P/E (TTM) x -1.1 54.6 - View Chart
P/BV x 0.0 2.2 0.8% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PLETHICO PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ALEMBIC LTD
Mar-18
PLETHICO PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs39572 548.5%   
Low Rs3134 92.3%   
Sales per share (Unadj.) Rs604.44.7 12,858.0%  
Earnings per share (Unadj.) Rs32.56.1 532.1%  
Cash flow per share (Unadj.) Rs51.36.2 821.8%  
Dividends per share (Unadj.) Rs00.20 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs473.640.7 1,164.6%  
Shares outstanding (eoy) m34.08267.03 12.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.411.3 3.1%   
Avg P/E ratio x6.68.7 75.6%  
P/CF ratio (eoy) x4.28.5 49.0%  
Price / Book Value ratio x0.51.3 34.6%  
Dividend payout %03.3 0.0%   
Avg Mkt Cap Rs m7,26214,139 51.4%   
No. of employees `000NANA-   
Total wages/salary Rs m1,596207 769.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,5981,255 1,641.0%  
Other income Rs m386370 104.4%   
Total revenues Rs m20,9841,625 1,291.0%   
Gross profit Rs m2,818111 2,536.1%  
Depreciation Rs m64238 1,699.2%   
Interest Rs m1,5932 93,717.6%   
Profit before tax Rs m969442 219.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-13824 -577.8%   
Profit after tax Rs m1,1071,630 67.9%  
Gross profit margin %13.78.9 154.5%  
Effective tax rate %-14.35.4 -263.6%   
Net profit margin %5.4129.8 4.1%  
BALANCE SHEET DATA
Current assets Rs m18,8771,867 1,011.0%   
Current liabilities Rs m11,896591 2,012.2%   
Net working cap to sales %33.9101.6 33.3%  
Current ratio x1.63.2 50.2%  
Inventory Days Days3694 38.1%  
Debtors Days Days19874 269.0%  
Net fixed assets Rs m9,8611,791 550.6%   
Share capital Rs m341534 63.8%   
"Free" reserves Rs m12,33110,324 119.4%   
Net worth Rs m16,13910,858 148.6%   
Long term debt Rs m4,70641 11,421.8%   
Total assets Rs m33,14611,591 286.0%  
Interest coverage x1.6260.9 0.6%   
Debt to equity ratio x0.30 7,684.4%  
Sales to assets ratio x0.60.1 573.8%   
Return on assets %8.114.1 57.9%  
Return on equity %6.915.0 45.7%  
Return on capital %12.315.2 80.9%  
Exports to sales %21.41.5 1,382.9%   
Imports to sales %15.221.0 72.6%   
Exports (fob) Rs m4,40219 22,692.8%   
Imports (cif) Rs m3,136263 1,190.9%   
Fx inflow Rs m4,40219 22,692.8%   
Fx outflow Rs m3,184264 1,206.8%   
Net fx Rs m1,219-244 -498.5%   
CASH FLOW
From Operations Rs m2,437236 1,033.7%  
From Investments Rs m-6,265-224 2,796.7%  
From Financial Activity Rs m2,490-27 -9,361.3%  
Net Cashflow Rs m-1,337-15 9,034.9%  

Share Holding

Indian Promoters % 82.7 64.0 129.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 0.2 2,150.0%  
FIIs % 5.5 9.7 56.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 26.1 28.7%  
Shareholders   10,665 54,701 19.5%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  BIOCON   

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips below 38,000-Mark; Yes Bank Jumps 9%(12:30 pm)

Share markets in India are presently trading deep in the red as investors were disappointed after the government refused any respite to foreign investors.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY18); Net Profit Up 64.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC LTD has posted a net profit of Rs 46 m (up 64.9% YoY). Sales on the other hand came in at Rs 332 m (up 0.9% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS